BiotechTube
Home/Pipeline/Novel Antibiotic Class 2

Novel Antibiotic Class 2

Bacterial Infections

Pre-clinicalActive

Key Facts

Indication
Bacterial Infections
Phase
Pre-clinical
Status
Active
Company
ArrePath

About ArrePath

ArrePath is a private, preclinical-stage biotech applying a proprietary AI/ML platform to accelerate and de-risk small molecule drug discovery. The company's core innovation lies in its ability to integrate disparate assay data and tightly embed AI into the entire discovery workflow, claiming at least 3x greater efficiency in identifying progressible compounds. To date, ArrePath has generated early validation with the discovery of two novel antibiotic classes and is actively expanding its pipeline into respiratory medicine and other therapeutic areas.

View full company profile

Therapeutic Areas

Infectious DiseasesRespiratory Medicine

Other Bacterial Infections Drugs

DrugCompanyPhase
Azithromycin Preparationscspc-pharmaceuticalCommercial
Penem Preparationscspc-pharmaceuticalCommercial
Various Penicillin/Cephalosporin Productscspc-pharmaceuticalCommercial
Nemonoxacin Malate CapsulesZhejiang MedicineCommercial
Generic Portfolio Expansion - Anti-infectivesAlkaloid AD SkopjeRegulatory Submission
Clindamycin Phosphate InjectionViwitCommercial
Levofloxacin Hydrochloride InjectionViwitCommercial
Meropenem-VaborbactamSciClone PharmaceuticalsCommercial (in China)
Vibativ® (telavancin)Cleo Life SciencesApproved
Penicillin V APIBiotikaCommercial
Sterile Injectable Antibiotics PortfolioSteripharmaApproved
Oral AntibioticDawah PharmaceuticalsANDA Filed/Pre-approval